Golimumab for the treatment of ulcerative colitis

References

• DaneseSFiocchiCUlcerative colitisN Engl J Med20113651713172522047562
   PubMed Web of Science ®Google Scholar
• ReinischWSandbornWJHommesDWAdalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trialGut20116078078721209123
   PubMed Web of Science ®Google Scholar
• RutgeertsPSandbornWJFeaganBGInfliximab for induction and maintenance therapy for ulcerative colitisN Engl J Med20053532462247616339095
   PubMed Web of Science ®Google Scholar
• SandbornWJvanAGReinischWAdalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitisGastroenterology201214225726522062358
   PubMed Web of Science ®Google Scholar
• ArmuzziAPuglieseDNardoneOMGuidiLManagement of difficult-to-treat patients with ulcerative colitis: focus on adalimumabDrug Des Devel Ther20137289296
   PubMed Web of Science ®Google Scholar
• HutasGGolimumab, a fully human monoclonal antibody against TNFalphaCurr Opin Mol Ther20081039340618683105
   PubMed Web of Science ®Google Scholar
• LonbergNHuman antibodies from transgenic animalsNat Biotechnol2005231117112516151405
   PubMed Web of Science ®Google Scholar
• ShealyDCaiAStaquetKCharacterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor alphaMAbs Epub78201024
   Web of Science ®Google Scholar
• KayJMattesonELDasguptaBGolimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging studyArthritis Rheum20085896497518383539
   PubMed Web of Science ®Google Scholar
• ZhuangYXuZFrederickBGolimumab pharmacokinetics after repeated subcutaneous and intravenous administrations in patients with rheumatoid arthritis and the effect of concomitant methotrexate: an open-label, randomized studyClin Ther201234779022169051
   PubMed Web of Science ®Google Scholar
• EmeryPFleischmannRMMorelandLWGolimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritisArthritis Rheum2009602272228319644849
   PubMed Web of Science ®Google Scholar
• KeystoneECGenoveseMCKlareskogLGolimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD StudyAnn Rheum Dis20096878979619066176
   PubMed Web of Science ®Google Scholar
• SmolenJSKayJDoyleMKGolimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trialLancet200937421022119560810
   PubMed Web of Science ®Google Scholar
• InmanRDDavisJCJrHeijdeDEfficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trialArthritis Rheum2008583402341218975305
   PubMed Web of Science ®Google Scholar
• KavanaughAMcInnesIMeasePGolimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled studyArthritis Rheum20096097698619333944
   PubMed Web of Science ®Google Scholar
• SandbornWJFeaganBGMaranoCSubcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitisGastroenterology20141469610923770005
   PubMed Web of Science ®Google Scholar
• SandbornWJFeaganBGMaranoCSubcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitisGastroenterology2014146859523735746
   PubMed Web of Science ®Google Scholar
• SchroederKWTremaineWJIlstrupDMCoated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized studyN Engl J Med1987317162516293317057
   PubMed Web of Science ®Google Scholar
• IrvineEJFeaganBRochonJCanadian Crohn’s Relapse Prevention Trial Study Group. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel diseaseGastroenterology19941062872968299896
   PubMed Web of Science ®Google Scholar
• PanaccioneRGhoshSMiddletonSCombination therapy with Infliximab and Azathioprine is superior to monotherapy with either agent in ulcerative colitisGastroenterology2013 [Epub ahead of print]
   Google Scholar
• SeowCHNewmanAIrwinSPSteinhartAHSilverbergMSGreen-bergGRTrough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitisGut201059495419651627
   PubMed Web of Science ®Google Scholar
• Peyrin-BirouletLAnti-TNF therapy in inflammatory bowel diseases: a huge reviewMinerva Gastroenterol Dietol20105623324320485259
   PubMedGoogle Scholar
• RahierJFBen-HorinSChowersYEuropean evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel diseaseJ Crohns Colitis20093479121172250
   PubMed Web of Science ®Google Scholar
• LalvaniAMillingtonKAScreening for tuberculosis infection prior to initiation of anti-TNF therapyAutoimmun Rev2008814715218706526
   PubMed Web of Science ®Google Scholar
• BlumbergHMBurmanWJChaissonREAmerican Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosisAm J Respir Crit Care Med200316760366212588714
   PubMed Web of Science ®Google Scholar
• TheisVSRhodesJMReview article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel diseaseAliment Pharmacol Ther200827193017944997
   PubMed Web of Science ®Google Scholar
• KornbluthASacharDBUlcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters CommitteeAm J Gastroenterol201010550152320068560
   PubMed Web of Science ®Google Scholar
• MagroFPeyrin-BirouletLSokolHExtra-intestinal malignancies in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop (III)J Crohns Colitis20148314423721759
   PubMed Web of Science ®Google Scholar
• Nordgaard-LassenIDahlerupJFBelardEGuidelines for screening, prophylaxis and critical information prior to initiating anti-TNF-alpha treatmentDan Med J201259C448022759856
   PubMed Web of Science ®Google Scholar